FGF-16 Inhibitors

FGF-16 inhibitors encompass a range of compounds primarily characterized by their ability to indirectly modulate the activity of Fibroblast Growth Factor 16. This modulation is achieved not through direct interaction with FGF-16 but by influencing the signaling pathways and cellular processes that FGF-16 is involved in. Many of these compounds are kinase inhibitors, targeting various tyrosine kinases and other enzymes that play crucial roles in the signaling cascades activated by FGF-16. For example, PD173074 and SU5402 are known FGFR inhibitors, blocking the receptor through which FGF-16 exerts its effects, thereby inhibiting the downstream signaling of FGF-16. Other compounds in this class, such as Sunitinib, Sorafenib, and Vandetanib, are multi-kinase inhibitors that target a range of enzymes involved in FGF-16 related pathways. These inhibitors do not specifically target FGF-16 but can significantly impact its signaling by inhibiting key components in its pathway. For instance, RAF kinase inhibitors like Sorafenib indirectly affect FGF-16 activity by impeding downstream signaling processes that are vital for FGF-16's biological function. Similarly, EGFR inhibitors such as Erlotinib and Gefitinib can indirectly influence FGF-16 mediated cellular processes by altering EGFR-mediated signaling pathways that intersect or interact with FGF-16 related pathways.